Dublin, March 16, 2023 (GLOBE NEWSWIRE) -- The "Microbiome Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the market.
The global microbiome market will grow from $0.39 billion in 2022 to $0.57 billion in 2023 at a compound annual growth rate (CAGR) of 45.6%. The microbiome market is expected to grow from $1.09 billion in 2027 at a CAGR of 17.6%.
Major players in the microbiome market are MicroBiome Therapeutics LLC, Seres Therapeutics, Enterome Bioscience, Second Genome, Vedanta Biosciences Inc, AbbVie Inc., Rebiotix, Inc., Ritter Pharmaceuticals, LNC Therapeutics Inc. and ViThera Pharmaceuticals Inc.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
The microbiome market consists of sales of firmicutes, bacteroidetes, and actinobacteria. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Microbiome refers to a group of microbes that live in a certain habitat and include fungi, bacteria, and viruses. It is all of the bacteria, fungi, protozoa, and viruses' genetic material that dwells on and within the human body. The microbiome's bacteria also aid in digestion, immune system control, defence against disease-causing bacteria, and the production of vitamins like Vitamin K, which is required for blood clotting, and the B vitamins B12, thiamine, and riboflavin.
The main types of microbiomes are fecal microbiota transplantation (FMT) and microbiome drugs. The technique of transferring faecal bacteria and other germs from one healthy person to another is known as faecal microbiota transplantation or stool transplantation. The different technologies include genomics, proteomics, and metabolomics and are used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and others.
The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel disease (IBD) is a multifactorial and autoimmune infection group consisting of two major entities such as ulcerative colitis (UC) and Crohn's disease (CD).
Fecal microbiota transplantation (FMT) and probiotics were discovered as having potential applications in many immune-mediated disorders, such as IBD, to restore microbial balance. These microbial therapies have shown the potential to reduce both the dysbiotic condition and the development of inflammatory mediators, thereby enabling remission, particularly in UC.
The high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of fecal transplantation, a microbial therapy, may vary considerably depending on the delivery method used by users and where users receive it. Fecal microbiota transplant processes can charge around $600-$1,000 based on the method of treatment, area, insurance coverage, and other variables. Therefore, the high cost of microbial therapy is expected to hinder the growth of the microbiome market.
The growing technological improvement is a major trend gaining popularity in the microbiome market. Major companies in the microbiome sector are focusing on developing advanced technology solutions for microbiomes. For instance, Seed, a new microbiome company, has introduced Probiotic and Prebiotic Daily Synbiotic for both females and males. The Daily Synbiotic Seed is the first to follow a microbe-system strategy with strain-specific advantages beyond digestive health such as cardiac safety, dermatological health, immune control, reproductive health, the integrity of the gut barrier, and oxidative stress.
In January 2021, Novozymes, a Denmark-based biotechnology company acquired Microbiome Labs for an undisclosed amount. Microbiome Labs' acquisition is a crucial step in expanding Novozymes' Human Health platform, giving it exposure to a wide range of patented solutions as well as access to the firm's network of health professionals. Microbiome Labs is a US-based probiotics company.
The regions covered in the microbiome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Topics Covered:
1. Executive Summary
2. Microbiome Market Characteristics
3. Microbiome Market Trends And Strategies
4. Microbiome Market - Macro Economic Scenario
4.1 COVID-19 Impact On Microbiome Market
4.2 Ukraine-Russia War Impact On Microbiome Market
4.3 Impact Of High Inflation On Microbiome Market
5. Microbiome Market Size And Growth
5.1. Global Microbiome Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Microbiome Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Microbiome Market Segmentation
6.1. Global Microbiome Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Fecal Microbiota Transplantation (FMT)
- Microbiome drugs
6.2. Global Microbiome Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Inflammatory Bowel Disease
- Diabetes
- Multiple Sclerosis
- Rheumatoid Arthritis
- Other Applications
6.3. Global Microbiome Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Genomics
- Proteomics
- Metabolomics
7. Microbiome Market Regional And Country Analysis
7.1. Global Microbiome Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Microbiome Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/tuy4op
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
